Genetic Hair Loss Tests: What 23andMe Actually Tells You
Written by the Balding AI Editorial Team · medically reviewed by Dr. Nga Nguyen (Dermatologist) · grounded in published clinical guidelines (AAD, NHS). This guide supports tracking and informed clinician conversations and is not medical advice or diagnosis.
Routine Playbook
Turn scattered checking into a weekly routine you can sustain
This guide is built around repeatability: one capture rhythm, one monthly review habit, and one clearer way to see whether your process is working.
Best for readers who need one cleaner next step instead of another round of anxious comparison.
What this guide helps you decide
Decide whether a consumer genetic test for hair loss is worth the money for your specific situation
Read this first if you want one clearer answer instead of another loop of broad browsing.
Best fit for this stage
Best for readers who need one cleaner next step instead of another round of anxious comparison.
Stay oriented while you read
Use this reading map to jump straight to the section you need now, or follow it top to bottom if you want the full logic.
Key Takeaways
- Androgenetic alopecia involves more than 350 known genetic loci, not a single 'balding gene', so any single-variant report is an incomplete read.
- The AR gene on the X chromosome (rs6152) is the single strongest male hair loss predictor, but it explains only a fraction of the total risk variance.
- 23andMe stopped reporting hair loss directly to most users in 2023, though the raw genotype data can still be exported and interpreted with third-party tools at your own risk.
- Polygenic risk scores (Nutrahair, Hairmetrix, Fagron TrichoTest) bundle dozens to hundreds of variants and predict better than single-SNP reports, but still cannot tell you how fast you will lose hair.
- No commercial test reliably predicts response to finasteride or minoxidil; the evidence base for pharmacogenomic hair loss panels is thin and not yet clinically validated.
Jump to sections
Consumer genetic tests for hair loss have a familiar pitch. Spit in a tube, get a report, and finally know whether you are heading for a Norwood 5 or a full head of hair at 60. The marketing also adds a second promise: the report will tell you which treatments are most likely to work, so you can skip the trial and error. Both claims overstate what the science actually supports. This guide walks through what these tests measure, what they cannot, and whether 100 to 300 USD changes a single real decision you are about to make.
The honest summary first: a hair loss genetic test can confirm that you carry common risk variants, but it cannot tell you when you will lose hair, how fast, what pattern, or what treatment will work for you. The most useful decision tool is still a clean baseline photo set and 90 days of structured tracking. The test result is a footnote on that record, not a replacement for it.
Track real changes, not just predicted risk
A DNA test is a one-time guess. A consistent monthly photo and shed log is the actual evidence. BaldingAI helps you build that record so the decisions on starting, switching, or stopping treatment have data behind them.
Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.
The biology these tests are trying to read
Androgenetic alopecia is one of the most heritable common conditions in medicine. Twin and family studies estimate heritability at roughly 80 percent for male pattern hair loss (Nyholt et al. 2003, Journal of Investigative Dermatology). Genome-wide association studies have steadily expanded the list of contributing variants. The largest meta-analysis to date (Yap et al. 2018, Nature Communications, using more than 200,000 UK Biobank participants) identified 287 independent genetic signals associated with male pattern hair loss. Newer analyses have pushed that figure past 350. None of these are single switches. They are small contributions that add up.
The single strongest signal in men is on the X chromosome at the androgen receptor (AR) gene, often referenced by the SNP rs6152. That variant alone roughly doubles the odds of early-onset male pattern hair loss. Because men inherit their X chromosome from their mother, the old saying that balding comes from your maternal grandfather is partially true. It just leaves out the other 300 plus contributors that come from both sides of the family.
For female pattern hair loss, the genetic architecture is less well mapped. The AR locus plays a role, but the overall heritability estimates and the variant catalogue are smaller than for men. Consumer reports for women are correspondingly less informative.
What 23andMe actually tells you today
23andMe used to publish a "Hair Loss" trait report that gave a likelihood estimate based on a handful of SNPs. As of the 2023 platform changes, that direct hair loss report was deprecated for most users in favor of broader "trait" reports on hair characteristics like thickness, texture, and graying. The current consumer experience does not include a Norwood-style prediction. If your account predates the change you may still see a legacy hair loss view, but new sign-ups will not.
The workaround that most hair loss forums recommend is exporting your raw genotype data from 23andMe (or AncestryDNA) and running it through a third-party interpreter. Tools like Promethease, SelfDecode, and Genetic Lifehacks will return a list of relevant SNPs including rs6152, rs1352015, rs1160312, rs6113491 and others associated with hair loss in the GWAS literature. Two important cautions. First, you give up privacy when you upload raw DNA to another service. Second, single-SNP readouts are noisy. A "high risk" rs6152 result and a "low risk" rs1160312 result tell you almost nothing about your actual 10-year hair trajectory because the variants interact and the total polygenic score matters more than any single line.
23andMe is also not a clinical test. The lab is CLIA-certified, but the reports are marketed for educational and ancestry purposes. The FDA cleared some of its health reports in 2017, but pattern hair loss is not on that cleared list. Treat the data accordingly.
Nutrahair, Hairmetrix, and the polygenic risk score generation
A newer wave of hair-specific tests positions itself as the upgrade. Nutrahair, Hairmetrix, Fagron TrichoTest, Orig3n, and a handful of private clinic offerings claim to read dozens to hundreds of variants and return a more useful prediction. Pricing typically sits between 89 and 299 USD. Reports usually include a risk percentile, a predicted onset window, and a treatment "personalisation" section.
The risk percentile portion is the strongest part of the report. A well-built polygenic risk score that uses the variants from large GWAS catalogues does correlate meaningfully with observed hair loss in cohort studies (Hagenaars et al. 2017, PLOS Genetics, using over 52,000 UK Biobank men). It is a real signal. The weaker part is the treatment personalisation. Most reports recommend variations of finasteride, minoxidil, microneedling, ketoconazole shampoo, and a long list of supplements. These recommendations are not meaningfully tailored to your genotype because there is no clinically validated pharmacogenomic panel for hair loss treatment response. The same recommendations could be printed for almost any client.
Fagron TrichoTest markets itself the most aggressively as a pharmacogenomic guide for compounded prescriptions, scanning around 15 genes related to hair loss and drug metabolism. The underlying research that supports this for hair loss specifically is limited, mostly small uncontrolled studies funded by the manufacturer. Independent replications are not yet published. The compounded prescription that follows from the report is often a sensible finasteride and minoxidil topical, but you can get the same prescription from a regular dermatologist without the DNA panel.
What these tests cannot tell you
It is worth being concrete about the limits, because the marketing tends to blur them.
When you will start losing hair. Heritability tells you the lifetime risk bucket. It does not tell you the timing. Two men with identical high-risk genotypes can have a 10-year gap in their onset because environmental and hormonal modifiers shape the timeline.
How fast you will progress. Speed of progression is poorly predicted by current panels. The same risk score is consistent with a slow lifelong drift and a fast crash between 22 and 26. Your best speed estimate comes from your own month-over-month photo record, not from a saliva sample.
Your final Norwood or Ludwig stage. Final stage is a function of genetic risk, hormones, treatment use, scalp biology, and time. No clinical model reliably outputs a final stage prediction from a DNA test.
Your response to finasteride or minoxidil. Response to 5-alpha reductase inhibitors and minoxidil is variable. Sulfotransferase activity on the scalp is one predictor for topical minoxidil response, but the consumer tests that try to read this indirectly through DNA are not yet validated against real outcomes. For the practical version of this question, the article on minoxidil non-responders and sulfotransferase is more useful than any current panel result.
Whether you will get side effects. Side effect risk for finasteride is not reliably predicted by current consumer genetic tests.
When a test is actually worth the money
There are a few situations where the spend can earn its keep. If you are in your late teens or early 20s with no visible thinning yet, but a strong family history on both sides, a polygenic risk score can help you decide whether to start a structured baseline now rather than waiting for visible loss. The information does not change the treatment menu, but it can change your willingness to start tracking early.
It can also help if you are deciding between starting medication immediately versus waiting for visible signs. A high-percentile result might push you off the fence. A low-percentile result in the absence of any visible thinning might justify a slower watch-and-wait approach. That is a real decision the test can support, even if it cannot make it for you. For the broader version of that decision, see wait or start treatment at first signs.
If you are female with diffuse thinning and an unclear cause, a hair-specific genetic test is usually a lower priority than a proper blood workup (ferritin, thyroid panel, androgens). The blood test checklist for women is a better starting point.
When the test is probably a distraction
If you already have visible thinning, the test changes very little. You already know you are in a meaningful risk bucket because the phenotype is showing up. The next step is structured tracking and, usually, a conversation about evidence-backed treatments. Spending 200 USD on a test result that confirms what your hairline is already telling you is rarely the best use of the budget. A baseline photo set and a 90-day tracking plan deliver more decision value than a percentile score does.
Likewise, if you are looking to the test for a guaranteed answer on which treatment will work, you will not find it. Trial and tracked response remains the only reliable method. For the practical setup, see the baseline guide before starting medication.
Privacy notes worth thinking about once
Genetic data does not stay just about hair. A saliva sample sent to 23andMe or another consumer lab also encodes information about ancestry, carrier status for serious conditions, and traits you may not want surfaced. The 23andMe 2023 data breach exposed account-linked information for millions of users. If the only reason you are testing is hair loss, the privacy trade is heavier than the answer is useful. If you already have a broader interest in ancestry or trait reports, the marginal privacy cost for adding hair loss to your dataset is smaller.
The honest bottom line
A consumer hair loss genetic test is a real measurement of a real risk signal. It is also a narrow snapshot that cannot replace what your own scalp will show you over 6 to 12 months of structured tracking. If you already have visible thinning, prioritise the baseline and the cadence over the saliva tube. If you are still deciding whether to engage with the problem at all, a polygenic risk score might tip you toward starting earlier. Either way, the decisions that actually change outcomes are the ones you make on your tracking record, not on your DNA report.
Sources: Nyholt DR et al. 2003, Journal of Investigative Dermatology, "Genetic basis of male pattern baldness". Yap CX et al. 2018, Nature Communications, "Dissection of genetic variation and evidence for pleiotropy in male pattern baldness" (PMID 30573740). Hagenaars SP et al. 2017, PLOS Genetics, "Genetic prediction of male pattern baldness" (PMID 28196072).
Track real changes, not just predicted risk
A DNA test is a one-time guess. A consistent monthly photo and shed log is the actual evidence. BaldingAI helps you build that record so the decisions on starting, switching, or stopping treatment have data behind them.
Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.
Use This Guide Well
For buyer education content, decision quality improves when comparison criteria are measurable and tied to a consistent tracking protocol.
- Use one primary metric set for all options you evaluate.
- Avoid switching frameworks mid-cycle, or your comparisons lose reliability.
- Commit to a checkpoint window and decide from trend direction, not one photo.
Safety note
This article is for education and tracking guidance. It does not replace diagnosis or treatment advice from a licensed clinician.
- Use matched photo conditions whenever possible.
- Review monthly trends instead of reacting to one photo day.
- Escalate persistent uncertainty or symptoms to clinician care.
Questions and Source Notes
How do I know if my treatment is working?
Compare monthly checkpoint photos taken under the same conditions. Look for these signals: reduced visibility of scalp through hair, maintained or improved hairline position, increased density in previously thin areas, and stabilization of previously active shedding. A treatment is working if it stops or slows further loss — regrowth is a bonus, not the only success metric. Give any treatment at least 6 months before evaluating.
When should I change or add to my current treatment?
If you have been consistent with a treatment for 6+ months and your tracking data shows continued decline, discuss adding a complementary treatment with your dermatologist. Do not change treatments based on a single bad photo or a few weeks of increased shedding. Decisions should come from trend data across multiple monthly checkpoints, not from day-to-day anxiety.
What does a dermatologist need to see at a follow-up?
Bring a visual timeline showing standardized photos from each monthly checkpoint, any density or coverage scores you have tracked, a log of treatment adherence (missed doses, dosage changes), and notes on side effects with dates. This turns a subjective conversation into an evidence-based review and helps your dermatologist make more precise adjustments.
Track real changes, not just predicted risk
A DNA test is a one-time guess. A consistent monthly photo and shed log is the actual evidence. BaldingAI helps you build that record so the decisions on starting, switching, or stopping treatment have data behind them.
Keep Reading From Here
Continue with the next article or matching tracking route that keeps this guide actionable instead of sending you back into broad browsing.
Next editorial reads
When to Consider a Hair Transplant: The Decision Framework
Foundational Guide · decision
Natural DHT Blockers for Hair Loss: What Actually Works?
Foundational Guide · consideration
Does Insurance Cover Hair Loss Treatment? US and UK
Foundational Guide · consideration
Red Light Therapy Caps for Hair: Do They Work?
Foundational Guide · consideration